Literature DB >> 19343079

Signalosomes as Therapeutic Targets.

Alejandra Negro1, Kimberly Dodge-Kafka, Michael S Kapiloff.   

Abstract

Cardiac hypertrophy is the predominant compensatory response of the heart to a wide variety of biomechanical stressors, including exercise, hypertension, myocardial infarction, intrinsic cardiomyopathy or congenital heart disease. Although cardiac hypertrophy can maintain cardiac output in response to elevated wall stress, sustained cardiac hypertrophy is often accompanied by maladaptive remodeling which can ultimately lead to heart failure. Cultured cardiac myocytes, transgenic and knock-out animal models, and pharmacological studies have not only revealed key molecules involved in hypertrophic signaling, but have also highlighted the redundancy in the hypertrophic signaling cascade. Currently, the majority of existing therapies for inhibition of pathologic cardiac hypertrophy and heart failure target molecules on the surface of cardiac myocytes, such as G-protein coupled receptors (GPCRs) and ion channels. Because these molecules are upstream of multiple intracellular signaling pathways, however, current therapy is often accompanied by significant off-target effects and toxicity. More recently, research has focused on identifying the intracellular effectors of these signaling cascades in the hope that more selective drugs may be rationally designed for therapeutic intervention.Within the cardiac myocyte, the formation of discrete multimolecular complexes, or 'signalosomes', is an important mechanism for increasing the specificity and efficiency of hypertrophic signal transduction. In response to extracellular stimuli, these signalosomes can alter gene and protein expression, cell size, and chamber remodeling, such as in the case of the signalosomes formed by the mAKAPβ and AKAP-lbc scaffold proteins. A better understanding of the basic molecular mechanisms regulating the compartmentation and scaffolding of signaling molecules could lead to the development of new clinical tools that may prevent the development of heart failure and minimize negative impacts on physiological processes.

Entities:  

Year:  2008        PMID: 19343079      PMCID: PMC2390861          DOI: 10.1016/j.ppedcard.2007.11.012

Source DB:  PubMed          Journal:  Prog Pediatr Cardiol        ISSN: 1058-9813


  43 in total

1.  A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes.

Authors:  M G Newlon; M Roy; D Morikis; D W Carr; R Westphal; J D Scott; P A Jennings
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

3.  The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling.

Authors:  Genevieve C Pare; Andrea L Bauman; Molly McHenry; Jennifer J Carlisle Michel; Kimberly L Dodge-Kafka; Michael S Kapiloff
Journal:  J Cell Sci       Date:  2005-12-01       Impact factor: 5.285

4.  Galpha(12/13) mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy.

Authors:  Yoshiko Maruyama; Motohiro Nishida; Yoshiyuki Sugimoto; Shihori Tanabe; Justin H Turner; Tohru Kozasa; Teiji Wada; Taku Nagao; Hitoshi Kurose
Journal:  Circ Res       Date:  2002-11-15       Impact factor: 17.367

5.  Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; John A Vest; Anetta Wronska; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-06       Impact factor: 11.205

6.  Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization.

Authors:  Jing Jin; F Donelson Smith; Chris Stark; Clark D Wells; James P Fawcett; Sarang Kulkarni; Pavel Metalnikov; Paul O'Donnell; Paul Taylor; Lorne Taylor; Alexandre Zougman; James R Woodgett; Lorene K Langeberg; John D Scott; Tony Pawson
Journal:  Curr Biol       Date:  2004-08-24       Impact factor: 10.834

7.  Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex.

Authors:  Dario Diviani; Liliane Abuin; Susanna Cotecchia; Laetitia Pansier
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

Review 8.  AKAP-Lbc: a molecular scaffold for the integration of cyclic AMP and Rho transduction pathways.

Authors:  Dario Diviani; Laurent Baisamy; Aline Appert-Collin
Journal:  Eur J Cell Biol       Date:  2006-02-07       Impact factor: 4.492

Review 9.  The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways.

Authors:  Kimberly L Dodge-Kafka; Michael S Kapiloff
Journal:  Eur J Cell Biol       Date:  2006-02-07       Impact factor: 4.492

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  10 in total

Review 1.  A-kinase anchoring proteins as potential drug targets.

Authors:  Jessica Tröger; Marie C Moutty; Philipp Skroblin; Enno Klussmann
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  A-kinase anchoring proteins: getting to the heart of the matter.

Authors:  John D Scott; Luis F Santana
Journal:  Circulation       Date:  2010-03-16       Impact factor: 29.690

Review 3.  The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years.

Authors:  James D Wilkinson; David C Landy; Steven D Colan; Jeffrey A Towbin; Lynn A Sleeper; E John Orav; Gerald F Cox; Charles E Canter; Daphne T Hsu; Steven A Webber; Steven E Lipshultz
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

4.  AKAP150 participates in calcineurin/NFAT activation during the down-regulation of voltage-gated K(+) currents in ventricular myocytes following myocardial infarction.

Authors:  Madeline Nieves-Cintrón; Dinesh Hirenallur-Shanthappa; Patrick J Nygren; Simon A Hinke; Mark L Dell'Acqua; Lorene K Langeberg; Manuel Navedo; Luis F Santana; John D Scott
Journal:  Cell Signal       Date:  2015-12-24       Impact factor: 4.315

Review 5.  RSK3: A regulator of pathological cardiac remodeling.

Authors:  Eliana C Martinez; Catherine L Passariello; Jinliang Li; Christopher J Matheson; Kimberly Dodge-Kafka; Philip Reigan; Michael S Kapiloff
Journal:  IUBMB Life       Date:  2015-05-19       Impact factor: 3.885

6.  Confinement of β(1)- and β(2)-adrenergic receptors in the plasma membrane of cardiomyocyte-like H9c2 cells is mediated by selective interactions with PDZ domain and A-kinase anchoring proteins but not caveolae.

Authors:  Cathleen D Valentine; Peter M Haggie
Journal:  Mol Biol Cell       Date:  2011-06-16       Impact factor: 4.138

7.  Targeting mAKAPβ expression as a therapeutic approach for ischemic cardiomyopathy.

Authors:  Eliana C Martinez; Jinliang Li; Jennifer Arthur Ataam; Kristin Tokarski; Hrishikesh Thakur; Ioannis Karakikes; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  Gene Ther       Date:  2022-02-01       Impact factor: 4.184

8.  Digital signaling decouples activation probability and population heterogeneity.

Authors:  Ryan A Kellogg; Chengzhe Tian; Tomasz Lipniacki; Stephen R Quake; Savaş Tay
Journal:  Elife       Date:  2015-10-21       Impact factor: 8.140

Review 9.  Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins.

Authors:  Ana I Calejo; Kjetil Taskén
Journal:  Front Pharmacol       Date:  2015-09-08       Impact factor: 5.810

10.  CIP4 is required for the hypertrophic growth of neonatal cardiac myocytes.

Authors:  Francesca Rusconi; Hrishikesh Thakur; Jinliang Li; Michael S Kapiloff
Journal:  J Biomed Sci       Date:  2013-08-03       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.